Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study. The primary objective is to evaluate the safety of UTAA91 injection in treating subjects with relapsed/refractory autoimmune inflammatory diseases (AID).
Age ≥ 18 years (including the cut - off value), with no restrictions on gender. [+5]
Malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) wi... [+2]